Clinical Trial Update: ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of ITI-007 for agitation in dementia, including Alzheimer's disease was terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• ITI-007

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Agitation in Dementia, Including Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-06-29